Phathom Pharmaceuticals (PHAT) Earnings Date, Estimates & Call Transcripts $2.76 -0.60 (-17.86%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.81 +0.05 (+1.81%) As of 05/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Phathom Pharmaceuticals Earnings Summary Latest Q3 Earnings DateNov. 7EstimatedConsensus EPS (Nov. 7) -$1.57 Actual EPS (Nov. 7) -$1.32 Beat By $0.25 Actual Revenue (Nov. 7) $16.35MPhathom Pharmaceuticals issued Q3 2024 earnings on November 7, 2024, reporting an EPS of -$1.32, which beat analysts' consensus estimates of -$1.57 by $0.25. Quarterly revenue was reported to be $16.35 million, above analyst estimates of $12.54 million. With a trailing EPS of -$5.35, Phathom Pharmaceuticals' earnings are expected to grow next year, from ($4.78) to ($4.02) per share. Q3 2024 Earnings ResourcesQ3 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Phathom Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPHAT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PHAT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Phathom Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($4.78) EPSNext Year EPS Consensus Estimate ($4.02) EPS Phathom Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/7/2024Q3 2024-$1.57-$1.32+$0.25-$1.32$12.54M$16.35M8/8/2024Q2 2024-$1.39-$1.35+$0.04-$1.14$5.65M$7.32M5/9/2024Q1 2024-$1.43-$1.42+$0.01-$1.42$2.76M$1.91M3/7/2024Q4 2023-$0.92-$0.80+$0.12-$0.21$0.93M$0.68M11/9/2023Q3 2023-$0.95-$0.76+$0.19-$0.76--8/10/2023Q2 2023-$0.95-$0.84+$0.11-$0.84--5/10/2023Q1 2023-$1.34-$0.89+$0.45-$0.89-- Phathom Pharmaceuticals Earnings - Frequently Asked Questions When did Phathom Pharmaceuticals announce their last quarterly earnings? Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on PHAT's earnings history. Did Phathom Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Phathom Pharmaceuticals (NASDAQ:PHAT) reported ($1.32) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.57) by $0.25. Learn more on analysts' earnings estimate vs. PHAT's actual earnings. How can I listen to Phathom Pharmaceuticals's earnings conference call? The conference call for Phathom Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Phathom Pharmaceuticals's conference call transcript? The conference call transcript for Phathom Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Phathom Pharmaceuticals generate each year? Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded annual revenue of $55.25 million. How much profit does Phathom Pharmaceuticals generate each year? Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded net income of -$201.59 million. PHAT has generated -$5.35 earnings per share over the last four quarters. What is Phathom Pharmaceuticals's EPS forecast for next year? Phathom Pharmaceuticals's earnings are expected to grow from ($4.78) per share to ($4.02) per share in the next year. More Earnings Resources from MarketBeat Related Companies SNDX Earnings Results ADPT Earnings Results AUPH Earnings Results ETNB Earnings Results WVE Earnings Results ELVN Earnings Results XFOR Earnings Results ZYME Earnings Results PHVS Earnings Results SYRE Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings This page (NASDAQ:PHAT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
